Jomrich G, Paireder M, Kristo I, et al. - In various malignancies, the systemic immune-inflammation index (SII) based on peripheral neutrophil, lymphocyte, and platelet counts has exhibited a prognostic ability. In patients with resectable adenocarcinoma of the gastroesophageal junction treated with or without neoadjuvant therapy, the clinical role of the systemic immune-inflammation index was examined. Researchers obtained data of consecutive patients undergoing esophagectomy (n = 320) from 1992 to 2016. Analysis revealed the independent value of elevated SII as an adverse prognostic factor in patients with resectable gastroesophageal adenocarcinomas with and without neoadjuvant treatment. High SII was significantly correlated with lower overall and disease-free survival in both neoadjuvantly treated and primarily resected patients.